TY - JOUR
T1 - Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins
AU - Asselbergs, Folkert W.
AU - van der Harst, Pim
AU - Jessurun, Gillian A. J.
AU - Tio, René A.
AU - van Gilst, Wiek H.
PY - 2005
Y1 - 2005
N2 - Impaired endothelial function is recognised as one of the earliest events of atherogenesis. Endothelium-dependent vasomotion has been the principal method to assess endothelial function. In this article, we will discuss the clinical value of the different techniques to evaluate endothelium-dependent vasomotion. To date, there seems not to be a simple and reliably endothelial function test to identify asymptomatic subjects at increased risk for cardiovascular disease in clinical practice. Recent studies indicate that pharmacological interventions, in particular with ACE-inhibitors and statins, might improve endothelial function. However, there is no solid evidence that improvement of endothelial function is a necessity for the observed reduction in cardiovascular events by these compounds. Overall, at this moment, there is no place in clinical practice for the use of endothelial function as a method for risk assessment or target of pharmacological interventions. © 2005 Elsevier Inc. All rights reserved.
AB - Impaired endothelial function is recognised as one of the earliest events of atherogenesis. Endothelium-dependent vasomotion has been the principal method to assess endothelial function. In this article, we will discuss the clinical value of the different techniques to evaluate endothelium-dependent vasomotion. To date, there seems not to be a simple and reliably endothelial function test to identify asymptomatic subjects at increased risk for cardiovascular disease in clinical practice. Recent studies indicate that pharmacological interventions, in particular with ACE-inhibitors and statins, might improve endothelial function. However, there is no solid evidence that improvement of endothelial function is a necessity for the observed reduction in cardiovascular events by these compounds. Overall, at this moment, there is no place in clinical practice for the use of endothelial function as a method for risk assessment or target of pharmacological interventions. © 2005 Elsevier Inc. All rights reserved.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=15744367520&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/15792930
U2 - https://doi.org/10.1016/j.vph.2005.01.009
DO - https://doi.org/10.1016/j.vph.2005.01.009
M3 - Review article
C2 - 15792930
SN - 1537-1891
VL - 42
SP - 125
EP - 140
JO - Vascular Pharmacology
JF - Vascular Pharmacology
IS - 3
ER -